


Copyright  
Not for Public  
Distribution  
Hesseler

Horizontal and Vertical  
**BONE AUGMENTATION**  
for Dental Implant Therapy



# Horizontal and Vertical **BONE AUGMENTATION** for Dental Implant Therapy

EDITED BY

**CRAIG M. MISCH, DDS, MDS**

Adjunct Clinical Professor  
University of Michigan School of Dentistry  
Ann Arbor, Michigan

Private Practice in Oral and Maxillofacial Surgery  
Sarasota, Florida



 **QUINTESSENCE PUBLISHING**

Berlin | Chicago | Tokyo  
Barcelona | London | Milan | Mexico City | Paris | Prague | Seoul | Warsaw  
*Beijing | Istanbul | Sao Paulo | Zagreb*



One book, one tree: In support of reforestation worldwide and to address the climate crisis, for every book sold Quintessence Publishing will plant a tree (<https://onetreepanted.org/>).

Copyright  
Not for publication  
Quintessence

#### Library of Congress Cataloging-in-Publication Data

Names: Misch, Craig M., 1960- editor.

Title: Horizontal and vertical bone augmentation for dental implant therapy / edited by Craig M. Misch.

Description: Batavia, IL : Quintessence Publishing Co Inc, [2024] |

Includes bibliographical references and index. | Summary: "Presents the assessment criteria and biologic principles required to make clinical decisions as well as the techniques and materials required to successfully perform horizontal and vertical bone augmentation"-- Provided by publisher.

Identifiers: LCCN 2023027493 | ISBN 9781647241254 (hardcover)

Subjects: MESH: Dental Implantation--methods | Bone Regeneration | Bone Transplantation | Dental Implants, Single-Tooth | Tooth Diseases--surgery

Classification: LCC RK667.I45 | NLM WU 640 | DDC 617.6/93--dc23/eng/20230908

LC record available at <https://lcn.loc.gov/2023027493>



©2024 Quintessence Publishing Co, Inc

Quintessence Publishing Co, Inc  
411 N Raddant Rd  
Batavia, IL 60510  
[www.quintessence-publishing.com](http://www.quintessence-publishing.com)

5 4 3 2 1

All rights reserved. This book or any part thereof may not be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without prior written permission of the publisher.

Editor: Leah Huffman  
Design: Sue Zubek  
Production: Sue Robinson

Printed in Croatia

# CONTENTS

*Preface vii*

*Contributors ix*

- 1 Bone Volume for Dental Implant Placement 1**  
*Craig M. Misch, Hom-Lay Wang, and Maggie Misch-Haring*
- 2 The Science of Bone: Form and Function 9**  
*Benjamin R. Coyac and Jill A. Helms*
- 3 Biologic Principles of Bone Augmentation 23**  
*Craig M. Misch, Hom-Lay Wang, and Maggie Misch-Haring*
- 4 The Biology of Bone Grafting Materials 31**  
*Richard J. Miron and Craig M. Misch*
- 5 Use of Platelet-Rich Fibrin for Bone Augmentation 55**  
*Richard J. Miron*
- 6 Recombinant Growth Factors and Novel Graft Constructs for Oral Bone Tissue Engineering 69**  
*Lorenzo Tavelli, Jessica Latimer, Shogo Maekawa, Chia-Yu Chen, David Kim, Hom-Lay Wang, and William V. Giannobile*
- 7 The Michigan Classification and Decision Trees for Horizontal and Vertical Bone Augmentation 97**  
*Craig M. Misch and Hom-Lay Wang*
- 8 Clinical Evaluation for Bone Augmentation 117**  
*Craig M. Misch and Mark Ludlow*
- 9 Systemic and Local Considerations for Bone Augmentation 133**  
*Tara Aghaloo and Craig M. Misch*

# CONTENTS

- 10** Patient Preparation for Bone Augmentation 143  
*Craig M. Misch and Richard J. Miron*
- 11** Guided Bone Regeneration for Horizontal and Vertical Bone Augmentation 151  
*Istvan A. Urban and Alberto Monje*
- 12** Mesh Grafting 169  
*Matteo Chiapasco, Alessandro Cucchi, and Craig M. Misch*
- 13** Block Bone Grafting 209  
*Craig M. Misch, Matteo Chiapasco, and Howard Gluckman*
- 14** Ridge Expansion 261  
*Craig M. Misch and Dan Cullum*
- 15** Interpositional Bone Grafting 285  
*Ole Jensen, Pietro Felice, Bach Le, and Carlo Barausse*
- 16** Distraction Osteogenesis 299  
*Ole Jensen and Bach Le*
- 17** Preparation of the Recipient Site for Bone Augmentation 313  
*Craig M. Misch, Bach Le, Rodrigo Neiva, and Matthew Fien*
- 18** Soft Tissue Reconstruction for Bone Augmentation 351  
*Istvan A. Urban, Alberto Monje, and Howard Gluckman*
- Index 366*

# PREFACE

**T**he field of implant dentistry continues to evolve and improve. One constant that has not changed is the need for sufficient bone volume at the site of implant placement to facilitate osseointegration and continued bone support over time. Bone augmentation is often required to accomplish this important goal. Many books on implant dentistry reflect an author's approach to a specific clinical problem—a “this is how I do it” book. I have always had a passion for research and teaching, and my goal for this text was to explain not only how I do it but also *why* and *when* we do it.

The first six chapters provide the reader fundamental knowledge of the science of bone augmentation, and chapters 7 to 10 cover the diagnosis and planning for bone augmentation surgery. The centerpiece of the text is the Michigan Classification for horizontal and vertical bone augmentation. Dr Hom-Lay Wang and I developed the Michigan Classification to offer clinicians an evidence-based decision tree for managing different clinical situations. This classification focuses on the treatment of bone defects and deficiencies outside the bony contour. The current research on outcomes using various methods of bone augmentation and biomaterials was evaluated to construct parameters and guidelines. Finally, chapters 11 to 18 discuss the various techniques for horizontal and vertical bone augmentation.

For this text I invited the most knowledgeable clinicians and researchers in their specific areas of expertise to coauthor the chapters. As such, it reflects a collective body of work rather than one author's preference or opinion. My goal was to provide a comprehensive source of authoritative information on the topic of bone augmentation. I also wanted to establish guidelines for students, clinicians, and researchers on predictable approaches to bone regeneration for dental implant therapy.

Technology has improved our ability to diagnose, plan, and execute treatment; using CBCT, we can create

a virtual patient for prosthetic guided bone augmentation. Customized scaffolds for bone regeneration can be fabricated based on the specific needs of each patient. Recombinant growth factors can be used to improve the regenerative capacity of osteoconductive biomaterials. Further advancements will undoubtedly improve outcomes. Surgeons should consider the advantages and disadvantages of each material and technique for the clinical situation and choose the approach with manageable costs, low morbidity, and the greatest chance for success. This text offers the reader a better understanding of how to accomplish these goals and improve the lives of their patients.

## Acknowledgments

The first person I wish to thank is my loving wife, Katie. We have been married for over 30 years and raised three intelligent and beautiful daughters: Maggie, Angela, and Rachel. Katie and I also practice together in the same office, Misch Implant Dentistry. We have just added Maggie Misch-Haring to the team as our periodontist and her husband, Harry Haring, as another prosthodontist. Throughout our marriage, Katie has supported my professional goals and helped me achieve a successful career. I could not have done it without her. I have always had a great interest in bone regeneration and dental implant therapy; Katie knew I always wanted to write a book on this topic and that my bucket list would not be complete until this was done. I realize it has not been easy putting our lives on hold while working on this project, but she continued to be supportive, and I am exceedingly grateful.

I also want to acknowledge my brother, Carl, for encouraging my interest in dentistry and fostering my education in dental implants. We worked together in Michigan for 3 years and thereafter did our prosthodontic



# PREFACE

residency training at the University of Pittsburgh. Carl also inspired me to become active in professional organizations and to teach, write, and lecture.

Following my prosthodontic residency and implantology fellowship, I stayed on as faculty at the University of Pittsburgh. My program director, Dr Chester Choraży, took a chance on accepting a prosthodontist into an oral and maxillofacial surgical residency. This opportunity was the missing piece of the puzzle in my training and professional career. Dr Choraży was like a father to us and mentored our education and surgical training.

I also want to thank Dr Hom-Lay Wang for his continued support and friendship. Dr Wang helped

immensely with writing and editing this text. Although he is extremely busy, he was always available to help. To all the coauthors in this text, I appreciate your expertise, dedication, and willingness to contribute and share your knowledge for this publication.

Last but not least, I would like to thank the Quintessence Publishing staff, including Leah Huffman (Editorial Director), Bryn Grisham (Publishing Director), and William Hartman (Executive Vice President and Director). With so many contributors, it was a challenge meeting timelines, but with dedication, persistence, and patience, our task was completed. I hope you enjoy the finished product.

# CONTRIBUTORS

## **Tara Aghaloo, DDS, MD, PhD**

Professor of Oral and Maxillofacial Surgery  
UCLA School of Dentistry  
Los Angeles, California

## **Carlo Barausse, DDS, PhD**

Department of Biomedical and Neuromotor Sciences  
University of Bologna  
Bologna, Italy

## **Chia-Yu Chen, DDS, DMSc**

Division of Periodontology  
Department of Oral Medicine, Infection, and Immunity  
Harvard School of Dental Medicine  
Boston, Massachusetts

## **Matteo Chiapasco, MD**

Professor, Unit of Oral Surgery  
Department of Biomedical, Surgical, and Dental Sciences  
University of Milan  
Milan, Italy

## **Benjamin R. Coyac, DDS, PhD**

Department of Periodontology and Laboratory for Bone  
Repair  
School of Graduate Dentistry  
Rambam Health Care Campus  
Haifa, Israel

## **Alessandro Cucchi, DDS, MSCLin, PhD**

Private Practice  
Bologna, Italy

## **Dan Cullum, DDS**

Private Practice in Oral and Maxillofacial Surgery  
Coeur d'Alene, Idaho

## **Pietro Felice, MD, DDS, PhD**

Department of Biomedical and Neuromotor Sciences  
University of Bologna  
Bologna, Italy

## **Matthew Fien, DDS**

Private Practice in Periodontics  
Fort Lauderdale, Florida

## **William V. Giannobile, DDS, MS, DMSc**

Dean and A. Lee Loomis, Jr, Professor of Oral  
Medicine, Infection, and Immunity  
Harvard School of Dental Medicine  
Boston, Massachusetts

## **Howard Gluckman, BDS, MChD, PhD**

Private Practice in Periodontics and Implant Dentistry  
Cape Town, South Africa

Adjunct Assistant Professor  
University of Pennsylvania School of Dental Medicine  
Philadelphia, Pennsylvania

Adjunct Professor  
University of the Western Cape  
Cape Town, South Africa

## **Jill A. Helms, DDS, PhD**

Professor and Vice Chair, DEI  
Department of Surgery  
Stanford School of Medicine  
Stanford University  
Palo Alto, California

## **Ole Jensen, DDS, MS**

Adjunct Professor  
University of Utah School of Dentistry  
Salt Lake City, Utah



# CONTRIBUTORS

## **David Kim, DDS, DMSc**

Associate Professor  
Division of Periodontology  
Harvard School of Dental Medicine  
Boston, Massachusetts

## **Jessica Latimer, DDS**

Division of Periodontology  
Department of Oral Medicine, Infection, and Immunity  
Harvard School of Dental Medicine  
Boston, Massachusetts

## **Bach Le, DDS, MD**

Clinical Associate Professor  
Department of Oral & Maxillofacial Surgery  
The Herman Ostrow School of Dentistry  
University of Southern California  
Los Angeles, California

Private Practice in Oral and Maxillofacial Surgery  
Whittier, California

## **Mark Ludlow, DMD, MS**

Section Head of Implant Dentistry, Digital Dentistry, and  
Removable Prosthodontics  
University of Utah School of Dentistry  
Salt Lake City, Utah

## **Shogo Maekawa, DDS, PhD**

Department of Periodontology  
Graduate School of Medical and Dental Sciences  
Tokyo Medical and Dental University  
Tokyo, Japan

## **Richard J. Miron, DDS, BMSc, MSc, PhD,**

*Dr med dent*

Department of Periodontology  
School of Dental Medicine  
University of Bern  
Bern, Switzerland

## **Craig M. Misch, DDS, MDS**

Adjunct Clinical Professor  
University of Michigan School of Dentistry  
Ann Arbor, Michigan

Private Practice in Oral and Maxillofacial Surgery  
Sarasota, Florida

## **Maggie Misch-Haring, DMD, MS**

Private Practice in Periodontics and Implant Surgery  
Sarasota, Florida

## **Alberto Monje, DDS, MS, PhD**

Department of Periodontology  
University of Michigan School of Dentistry  
Ann Arbor, Michigan

Adjunct Professor, Department of Periodontology  
UIC Barcelona  
Barcelona, Spain

## **Rodrigo Neiva, DDS, MS**

Chair and Clinical Professor of Periodontics  
Penn Dental Medicine  
University of Pennsylvania  
Philadelphia, Pennsylvania

## **Lorenzo Tavelli, DDS, MS, PhD**



Division of Periodontology  
Department of Oral Medicine, Infection, and Immunity  
Harvard School of Dental Medicine  
Boston, Massachusetts

## **Istvan A. Urban, MD, DMD, PhD**

Urban Regeneration Institute  
Budapest, Hungary

## **Hom-Lay Wang, DDS, MDS, PhD**

Professor and Director of Graduate Periodontics  
University of Michigan School of Dentistry  
Ann Arbor, Michigan



# BONE VOLUME FOR DENTAL IMPLANT PLACEMENT

*Craig M. Misch | Hom-Lay Wang | Maggie Misch-Haring*

**T**he replacement of missing or failing teeth with dental implants has revolutionized the field of dentistry and improved the quality of our patients' lives. High success rates and excellent predictability of dental implant therapy have been demonstrated in numerous clinical studies and a variety of indications. A number of factors important for the long-term survival and/or success of implants and implant-supported prostheses have been identified. One critical prerequisite is a sufficient volume of bone at the site of implant placement to facilitate osseointegration and continued bone support over time. In a prosthetic-driven approach to treatment, the planned prosthesis guides the number and 3D position of the implants. If the preferred implant locations have inadequate available bone, then bone augmentation may be required so that the implant can be placed in the ideal position for esthetics, prosthetic support, and long-term function.

## **Bone Volume**




The volume of bone in the edentulous site planned for implant placement is measured in 3D in terms of width, height, and angulation.


### **Bone width**

The minimum bone width is dependent on the preferred implant diameter and location. A minimum 2.0-mm

facial bone thickness has been recommended around implants in the esthetic zone to avoid crest resorption and gingival recession.<sup>1,2</sup> However, this recommendation was based on 1.4-mm horizontal bone loss found around external hex connection implants<sup>3</sup> (Fig 1-1). Tissue-level, conical-connection, and platform-switching implants are associated with less bone resorption.<sup>4-6</sup> A clinical study found that the horizontal component of bone loss around platform-switching implants measured only 0.6 mm.<sup>7</sup> Therefore, using implant designs with a conical seal, medialized connection, or absence of a microgap, such as a tissue-level implant, may reduce the ridge width requirement to 1.0 to 1.5 mm of facial and palatal/lingual bone (Fig 1-2). In addition, the edentulous ridge typically widens apically from the crest, so vertical bone reduction may be an alternative to bone augmentation in areas where esthetics is not a concern. However, in some cases the facial and palatal/lingual cortices may show minimal divergence.

Another alternative to bone augmentation of the atrophic ridge with deficient width is to use a narrow-diameter implant (NDI; Fig 1-3). A recent systematic review and meta-analysis found that implant diameters of 3.0 to 3.5 mm showed no difference in implant survival compared to standard-diameter implants (> 3.5 mm).<sup>8</sup> Additional systematic reviews and meta-analyses of studies have also found that NDIs are an effective alternative to standard-diameter implants due to similar survival and success rates, marginal bone loss, and mechanical






**FIG 1-3 (cont)** (c) Surgical view of the atrophic maxilla. The nasal and sinus floors were identified, and the mucosa was reflected superiorly. (Surgery performed by Dr Maggie Misch-Haring.) (d) Placement of an NDI (3.3 × 8.0 mm) with a nasal lift. (e) Six NDIs (3.3 × 8.0 mm) were placed in the atrophic maxilla. (f) The implants were restored with an implant-connecting bar. (g) Occlusal view of the implant-connecting bar. Note the medial position of the implants due to maxillary atrophy. (h) Intaglio view of the maxillary overdenture with attachments. (i) Clinical view of the maxillary overdenture.

and biologic complication rates.<sup>9,10</sup> Stronger metals, such as titanium-zirconium or titanium alloy, may reduce the risk of implant fracture when NDIs are used. Systematic reviews on titanium-zirconium NDIs have found implant success and survival rates to be similar to those of standard-diameter titanium implants with no increase in fractures.<sup>11,12</sup> However, long-term survival and data on the possible risk of technical complications with wide-platform restorations on NDIs are lacking. As such, a standard- or wide-diameter implant for single molar replacement may be prudent.


### Bone height

The minimum bone height for implant placement is dependent on several factors. One consideration is the anatomical region. In the posterior maxilla, the floor of the sinus can limit the available bone height. However, the sinus floor is an anatomical boundary that can be

encroached upon or manipulated via an internal or lateral sinus elevation. Many studies have shown that the survival of short implants (< 8 mm in length) is the same as that of longer implants placed into grafted sinuses.<sup>13,14</sup> Although there is no definitive bone dimension needed before considering sinus bone grafting, 6.0 to 8.0 mm inferior to the sinus floor appears to be sufficient (Fig 1-4). In the posterior mandible, the mandibular canal and lingual cortex can limit implant length. A common rule is to allow for at least a 2.0-mm distance from the mandibular canal for implant placement to account for potential inaccuracies in radiographic measurements, drilling depth, and implant placement.<sup>15</sup> As mandibular bone is usually of better quality, extra-short implants (6.0 mm in length) have been shown to be effective<sup>16</sup> (Fig 1-5). As such, 8.0 mm of available bone height superior to the canal is needed to place extra-short implants in the posterior mandible (Fig 1-6).



**FIG 1-4** Vertical bone height requirements in the posterior maxilla.




**FIG 1-5** (a) Preoperative view of the atrophic posterior mandible. (b) Preoperative CT scan of the atrophic posterior mandible. (c) Clinical view of the atrophic right posterior mandible. (d) The atrophic ridge was grafted with particulate autogenous bone and cortical mineralized bone allograft covered with a titanium-reinforced dense polytetrafluoroethylene (dPTFE) membrane. (e) After 6 months of healing, the membrane was removed for implant placement. (f) Two short tissue-level implants (4.1 × 6.0 mm) were placed into the grafted mandible. (g) Occlusal view of the two short tissue-level implants in the right posterior mandible. (h) The implants were restored with individual screw-retained crowns.


The amount of bone resorption following the loss of teeth determines the crown height or prosthetic space. *Implant crown-abutment height space* is defined as the distance from the occlusal plane to the platform of the

implant(s). The available restorative space will influence the type of prosthesis, material choices, and surgical techniques. It also has esthetic and biomechanical implications. In the esthetic zone, the decision needs to be made

**FIG 1-6** Vertical bone height requirements in the posterior mandible.




**FIG 1-7** Using short implants in an atrophic ridge increases the crown–abutment height space. Placing a short implant into an atrophic ridge will result in greater crown–abutment height (D). Because moment = force × distance, a greater distance (D) will increase the moment or torque on the implant–abutment connection.



regarding whether to reconstruct a vertical bone defect in an attempt to replicate normal anatomy or to replace the missing hard and soft tissue with the prosthesis. As vertical bone augmentation is more technically difficult, a prosthetic solution may provide a more predictable and straightforward approach in some cases. When crown–abutment height space is excessive, the resultant load on the prosthetic connection increases (Fig 1-7). This can result in a greater risk of technical complications such as abutment screw loosening and component fracture. When the crown–abutment height space becomes greater, the implant crowns may be splinted to decrease the risk of mechanical complications. However, systematic reviews have found that marginal bone loss and implant survival do not appear to be influenced by the crown-to-implant ratio.<sup>17–19</sup>

### Ridge angulation

In some cases, the angulation of the ridge in the edentulous site may not allow for the ideal implant trajectory. This problem is most often encountered in the atrophic maxilla. As the facial bone resorbs following extraction, the long axis of the ridge can become more tilted facially in line with the palatal contour (Fig 1-8). If the implant is placed in a more vertical orientation, the facial bone may be too thin or the apex may perforate the buccal cortex. This issue may be a more significant problem with single-tooth implants and small-span implant-supported partial dentures in the anterior maxilla. Bone augmentation may be needed to restore the ridge contour and allow for a better implant trajectory. An alternative approach is to place the implant at an angle within the bone and



use an angulated abutment to alter the path of prosthetic attachment or use an angulated screw channel. Although in the past there was concern regarding off-axis loading of dental implants, more recent studies have found no decrease in implant survival or higher marginal bone loss with tilted implants.<sup>20</sup>

### Soft Tissue Thickness


Another important factor for stability of the peri-implant bone is vertical soft tissue thickness. Several studies have suggested that approximately 4.0 mm of supracrestal soft tissue height is required to allow the formation of a biologic seal.<sup>21,22</sup> A more accurate term may be *supracrestal tissue adhesion* due to horizontal fiber orientation around the dental implant.<sup>22</sup> Thin tissue may induce bone remodeling around the implant neck to obtain adequate biologic width.<sup>23–26</sup> When managing a deficient ridge with a thin phenotype, it may be necessary to plan for soft tissue as well as hard tissue augmentation.

### The Consequences of Tooth Loss

Insufficient bone for dental implant placement can be a consequence of periodontitis, infection, trauma, pathology, tooth loss, jaw atrophy, congenital absence of teeth, or previous dental implant failure. Following tooth loss, the bundle bone lining the socket is rapidly resorbed. The greatest amount of alveolar bone loss occurs on the facial aspect due to the limited thickness of the buccal cortex compared to the lingual/palatal aspects of the socket walls.<sup>27</sup> The thickness of the facial cortex in the crestal area of teeth in the anterior maxilla has been shown to be thin (< 1 mm) in approximately 90% of patients.<sup>28,29</sup> Sockets that have thin facial bone are prone to more resorption

following tooth loss. Although this results in more horizontal resorption, there is also loss of vertical ridge height, which has been reported to be most pronounced on the buccal aspect.<sup>30</sup> A CBCT study found that thin facial wall thickness (< 1 mm) was associated with significant vertical bone resorption, with a median vertical bone loss of 7.5 mm, as compared with thicker socket walls (> 1 mm), which showed vertical bone resorption of only 1.1 mm after 8 weeks of healing.<sup>31</sup> Human studies on alveolar bone resorption following extraction have shown horizontal bone loss of 29% to 63% and vertical bone loss of 11% to 22% after 6 months of healing.<sup>32</sup> These studies demonstrated rapid reductions in the first 3 to 6 months, followed by a gradual reduction in dimensions thereafter, when remodeling of the ridge begins to plateau. However, longitudinal studies have found a continued reduction of the residual ridge in patients wearing soft tissue–borne removable prostheses.<sup>33,34</sup>

Bone resorption following tooth loss can compromise the bone volume for implant placement and may also have a deleterious effect on the implant position. In the maxilla, there is a greater loss of facial bone initially, so the residual ridge loses width and moves in a medial direction. As a consequence, the long axis of the ridge for implant placement tilts more to the facial (see Fig 1-8). With additional resorption, there is a loss of bone height and continued palatal shift of the ridge crest (Fig 1-9a). This can compromise implant positioning as the restorations need to be facial to the ridge crest. In the mandible, the initial loss of facial bone also results in a loss of ridge width as the residual ridge moves in a medial direction. However, with continued atrophy and loss of bone height, the lingual inclination of the mandible leads to a gradual inferior and lateral shift of the ridge crest (see Fig 1-9a). In the sagittal plane, the anterior maxilla



**FIG 1-9** (a) In the posterior region, the maxilla resorbs in a medial direction. The mandible initially resorbs medially, but with vertical loss it becomes wider. (b) The sagittal view shows that the anterior maxilla resorbs in a palatal direction, while the anterior mandible initially resorbs medially, but with vertical loss it moves in a facial direction.

resorbs in a superior and posterior direction while the anterior mandible resorbs in an inferior and anterior direction (Fig 1-9b). In the edentulous patient who has experienced moderate to severe ridge resorption in both the maxilla and mandible, a resultant skeletal Class III relationship occurs along with a prognathic appearance. Such bone atrophy can cause compromised interarch relationships in the vertical, transverse, and sagittal planes, which may complicate dental implant placement from a functional and esthetic perspective.

Bone loss and soft tissue alterations following tooth loss in the anterior maxilla can have a significant impact on the esthetic outcome of implant-supported restorations. To restore ridge contour and provide adequate bone volume for implant placement, bone and soft tissue augmentation is often a prerequisite to achieving a satisfactory esthetic result. These cases can be especially challenging when lip mobility exposes the maxillary gingiva or vertical bone augmentation is needed.

As bone loss following tooth extraction can negatively influence bone volume for implant placement and position, esthetics, and biomechanics, it is prudent to consider measures to maintain alveolar bone. The use of alveolar ridge preservation (ARP) can minimize dimensional changes following tooth extraction to provide adequate bone volume for dental implant placement. Extraction sites treated with socket bone grafts (ARP) have been shown to have significantly less dimensional change both vertically and horizontally when compared with controls not treated with ARP procedures.<sup>35</sup> In conjunction with minimally traumatic tooth extraction, this may reduce

the need for subsequent bone augmentation procedures or decrease the amount of bone gain required for future dental implant placement.

## References

1. Spray JR, Black CG, Morris HF, Ochi S. The influence of bone thickness on facial marginal bone response: Stage 1 placement through stage 2 uncovering. *Ann Periodontol* 2000;5:119–128.
2. Grunder U, Gracis S, Capelli M. Influence of the 3-D bone-to-implant relationship on esthetics. *Int J Periodontics Restorative Dent* 2005;25:113–119.
3. Tarnow DP, Cho SC, Wallace SS. The effect of inter-implant distance on the height of inter-implant bone crest. *J Periodontol* 2000;71:546–549.
4. Santiago JF Jr, de Souza Batista VE, Verri FR, et al. Platform-switching implants and bone preservation: A systematic review and meta-analysis. *Int J Oral Maxillofac Surg* 2016;45:332–345.
5. Caricasulo R, Malchiodi L, Ghensi P, Fantozzi G, Cucchi A. The influence of implant-abutment connection to peri-implant bone loss: A systematic review and meta-analysis. *Clin Implant Dent Relat Res* 2018;20:653–664.
6. Saleh MHA, Ravidà A, Suárez-López Del Amo F, Lin GH, Asa'ad F, Wang HL. The effect of implant-abutment junction position on crestal bone loss: A systematic review and meta-analysis. *Clin Implant Dent Relat Res* 2018;20:617–633.
7. Rodríguez-Ciurana X, Vela-Nebot X, Segalà-Torres M, et al. The effect of interimplant distance on the height of the interimplant bone crest when using platform-switched implants. *Int J Periodontics Restorative Dent* 2009;29:141–151.
8. Schiegnitz E, Al-Nawas B. Narrow-diameter implants: A systematic review and meta-analysis. *Clin Oral Implants Res* 2018;29(suppl 16):21–40.
9. Cruz RS, Lemos CAA, de Batista VES, Yogui FC, Oliveira HFF, Verri FR. Narrow-diameter implants versus regular-diameter implants for rehabilitation of the anterior region: A systematic review and meta-analysis. *Int J Oral Maxillofac Surg* 2021;50:674–682.
10. González-Valls G, Roca-Millan E, Céspedes-Sánchez JM, González-Navarro B, Torrejon-Moya A, López-López J. Narrow diameter dental implants as an alternative treatment for atrophic alveolar ridges. Systematic review and meta-analysis. *Materials (Basel)* 2021;14(12):3234.
11. Altuna P, Lucas-Taulé E, Gargallo-Albiol J, Figueras-Álvarez O, Hernández-Alfaro F, Nart J. Clinical evidence on titanium-zirconium dental implants: A systematic review and meta-analysis. *Int J Oral Maxillofac Surg* 2016;45:842–850.



12. Iegami CM, Uehara PN, Sesma N, Pannuti CM, Tortamano Neto PT, Mukai MK. Survival rate of titanium-zirconium narrow diameter dental implants versus commercially pure titanium narrow diameter dental implants: A systematic review. *Clin Implant Dent Relat Res* 2017;19:1015–1022.
13. Thoma DS, Zeltner M, Hüsler J, Hämmerle CHF, Jung RE. EAO Supplement Working Group 4—EAO CC 2015 short implants versus sinus lifting with longer implants to restore the posterior maxilla: A systematic review. *Clin Oral Implants Res* 2015;26(suppl 11):154–169.
14. Khouly I, Veitz-Keenan A. Insufficient evidence for sinus lifts over short implants for dental implant rehabilitation. *Evid Based Dent* 2015;16:21–22.
15. Juodzbalys G, Wang HL, Sabalys G, Sidlauskas A, Galindo-Moreno P. Inferior alveolar nerve injury associated with implant surgery. *Clin Oral Implants Res* 2013;24:183–190.
16. Ravidà A, Wang IC, Barootchi S, et al. Meta-analysis of randomized clinical trials comparing clinical and patient-reported outcomes between extra-short ( $\leq 6$  mm) and longer ( $\geq 10$  mm) implants. *J Clin Periodontol* 2019;46:118–142.
17. Blanes RJ, Bernard JP, Blanes ZM, Belsler UC. A 10-year prospective study of ITI dental implants placed in the posterior region. II: Influence of the crown-to-implant ratio and different prosthetic treatment modalities on crestal bone loss. *Clin Oral Implants Res* 2007;18:707–714.
18. Quaranta A, Piemontese M, Rappelli G, Sammartino G, Procaccini M. Technical and biological complications related to crown to implant ratio: A systematic review. *Implant Dent* 2014;23:180–187.
19. Garaicoa-Pazmiño C, Suárez-López del Amo F, Monje A, et al. Influence of crown-implant ratio upon marginal bone loss. A systematic review. *J Periodontol* 2014;85:1214–1221.
20. Lin WS, Eckert SE. Clinical performance of intentionally tilted implants versus axially positioned implants: A systematic review. *Clin Oral Implants Res* 2018;29(suppl 16):78–105.
21. Berglundh T, Lindhe J. Dimension of the periimplant mucosa. Biological width revisited. *J Clin Periodontol* 1996;23:971–973.
22. Saleh MH, Galli M, Siqueira R, Rodriguez MV, Wang HL, Ravidà A. The prosthetic-biologic connection and its influence on peri-implant biologic health: An overview of the current evidence. *Int J Oral Maxillofac Implants* 2022;37:690–699.
23. Linkevicius T, Apse P, Grybauskas S, Puisys A. The influence of soft tissue thickness on crestal bone changes around implants: A 1-year prospective controlled clinical trial. *Int J Oral Maxillofac Implants* 2009;24:712–719.
24. Vervaeke S, Dierens M, Besseler J, De Bruyn H. The influence of initial soft tissue thickness on peri-implant bone remodeling. *Clin Implant Dent Relat Res* 2014;16:238–247.
25. Puisys A, Linkevicius T. The influence of mucosal tissue thickening on crestal bone stability around bone-level implants. A prospective controlled clinical trial. *Clin Oral Implants Res* 2015;26:123–129.
26. Sun P, Yu D, Luo X, Xu A, Feng Y, He FM. The effect of initial biologic width on marginal bone loss: A retrospective study. *Int J Oral Maxillofac Implants* 2022;37:190–198.
27. Schropp L, Wenzel A, Kostopoulos L, Karring T. Bone healing and soft tissue contour changes following single-tooth extraction: A clinical and radiographic 12-month prospective study. *Int J Periodontics Restorative Dent* 2003;23:313–323.
28. Braut V, Bornstein MM, Belsler U, Buser D. Thickness of the anterior maxillary facial bone wall—A retrospective radiographic study using cone beam computed tomography. *Int J Periodontics Restorative Dent* 2011;31:125–131.
29. Huynh-Ba G, Pjetursson BE, Sanz M, et al. Analysis of the socket bone wall dimensions in the upper maxilla in relation to immediate implant placement. *Clin Oral Implants Res* 2010;21:37–42.
30. Araújo MG, Lindhe J. Dimensional ridge alterations following tooth extraction. An experimental study in the dog. *J Clin Periodontol* 2005;32:212–218.
31. Chappuis V, Engel O, Reyes M, Shahim K, Nolte LP, Buser D. Ridge alterations post-extraction in the esthetic zone: A 3D analysis with CBCT. *J Dent Res* 2013;92(12 suppl):195S–201S.
32. Tan WL, Wong TLT, Wong MCM, Lang NP. A systematic review of post-extraction alveolar hard and soft tissue dimensional changes in humans. *Clin Oral Implants Res* 2012;23(suppl 5):1–21.
33. Carlsson GE, Persson G. Morphologic changes of the mandible after extraction and wearing of dentures. A longitudinal, clinical, and x-ray cephalometric study covering 5 years. *Odontol Revy* 1967;18:27–54.
34. Tallgren A. The continuing reduction of the residual alveolar ridges in complete denture wearers: A mixed-longitudinal study covering 25 years. *J Prosthet Dent* 1972;27:120–132.
35. Avila Ortiz G, Chambrone L, Vignoletti F. Effect of alveolar ridge preservation interventions following tooth extraction: A systematic review and meta-analysis. *J Clin Periodontol* 2019;46(suppl 21):195–223.

Page numbers followed by “t” denote tables, “f” denote figures, and “b” denote boxes.

## A

- Abaloparatide, 91  
 ABBM. *See* Anorganic bovine bone mineral.  
 aBMSCs. *See* Alveolar bone-derived mesenchymal stem cells.  
 Abutment teeth, 333f  
 Acetaminophen, 144, 144t  
 Additive manufacturing, 84–86  
 Alcohol, 138–139, 141  
 Allogeneic block grafts  
   autogenous bone block grafts versus, 107, 244–246  
   description of, 244–245  
   exposure of, 343, 344f  
   for interpositional bone grafting, 287, 295f  
   rhBMP-2 with, 246  
   scaffolding uses of, 287f  
   survival rates for, 245  
 Allografts  
   advantages and disadvantages of, 37  
   cancellous, 155  
   cell recruitment by, 48  
   cortical, 155  
   demineralized freeze-dried bone, 36, 37b, 42  
   description of, 18–19, 35–36  
   freeze-dried bone, 36, 37b, 42, 49f  
   guided bone regeneration uses of, 155  
   particle size for, 36–37  
   particulate, 245f  
   platelet-rich fibrin and, 61f  
   properties of, 32f, 32t  
   resorption of, 44  
   rhBMP-2 and, 76  
   vertical bone augmentation uses of, 106  
 Alloplast(s)  
   description of, 39–40  
   freeze-dried bone, 36, 37b, 42  
   properties of, 32f, 32t  
   resorption of, 98  
 Alloplastic block grafts, 246  
 Alveolar bone, 14f, 16–17  
 Alveolar bone-derived mesenchymal stem cells, 90  
 Alveolar ridge  
   buccal expansion of, 269f  
   Cologne Classification of Alveolar Ridge Defects, 97  
   disuse atrophy of, 16–17  
   expansion of. *See* Ridge expansion.  
   horizontal deficiency of, 108f, 211f, 221f  
   postextraction atrophy of, 16–17  
   resorption of, 17  
 Alveolar ridge augmentation  
   antibiotic regimens for, 144t  
   bone marrow aspirate concentrate and deproteinized bone bovine mineral for, 90  
   guided bone regeneration for, 166t  
   horizontal. *See* Horizontal bone augmentation.  
   platelet-rich fibrin for, 61–63  
   rhBMP-2 for, 79  
   rhPDGF-BB for, 82  
   “safe track” approach to, 353, 354f–355f  
   vertical. *See* Vertical bone augmentation.  
   wound dehiscence associated with, 339–340  
 Alveolar ridge preservation  
   bone graft for, 75  
   indications for, 7  
   platelet-rich fibrin for, 59–60, 61f  
   rhBMPs for, 71t, 74  
   rhPDGF-BB for, 73t, 80, 81f–82f  
 AM. *See* Additive manufacturing.  
 Ameloblasts, 20  
 Amnion-chorion membrane, 263, 274, 279, 329–330  
 Amoxicillin, 144t  
 Anabolic agents, 90–91  
 Angiogenesis, 23f, 327  
 Ankylosed teeth, 16  
 Anorganic bovine bone mineral, 155, 161f, 163f, 165f, 196  
 Anterior flap advancement, 338  
 Anterior iliac crest bone graft harvest, 229  
 Anterior mandible  
   interpositional bone grafting in, 293–294, 297  
   lingual flap release in, 323  
 Anterior maxilla  
   atrophic, 218f, 321f, 336f  
   bone augmentation in, 124, 332f  
   bone deficiency in, 347f  
   customized titanium mesh in, 183f–187f  
   interpositional bone grafting in, 108, 289–293, 290f–292f, 297  
   3D defect in, 127f  
   tooth loss in, 7  
   Urban’s classification of, 321t  
   vertical bone deficiencies in  
     description of, 109, 342f  
     vertical bone augmentation for, 162–165, 163f–165f  
 Anterior superior iliac spine, 229, 231  
 Antibiotics, 143, 144t, 341  
 Anticoagulants, 55, 140, 140f  
 Antiplatelet therapy, 140, 140f  
 Antiresorptive medications, 136–137  
 Antisialogogues, 341  
 Appendicular skeleton, 11  
 Appositional bone growth, 9  
 ARP. *See* Alveolar ridge preservation.  
 Atrophic maxilla, 188f–189f, 233f, 344f  
 Autogenous block bone grafts. *See also* Block bone graft/grafting.  
   advantages of, 254t  
   allogeneic block grafts versus, 107, 244–246  
   barrier membrane coverage over, 250  
   biology of, 209–210  
   cortical, 246  
   disadvantages of, 209, 254t  
   donor sites for. *See* Autogenous bone harvesting.  
   harvesting of. *See* Autogenous bone harvesting.  
   instrumentation for, 210  
   resorption of, 250–251  
   split bone block technique for, 237–244, 239f–244f, 251  
   volume gains with, 251  
 Autogenous bone grafts  
   advantages of, 209  
   anorganic bovine bone mineral added to, 196  
   biology of, 209–210  
   bone morphogenetic proteins in, 155, 209  
   bone substitutes and, 34, 106, 196  
   bovine bone mineral and, 169  
   cancellous, 44  
   cell recruitment by, 48  
   clindamycin soaking of, 145  
   description of, 34–35, 209  
   disadvantages of, 69  
   donor sites for. *See* Autogenous bone harvesting.  
   free, 209–210  
   guided bone regeneration use of, 44, 63f, 69, 155  
   harvesting of. *See* Autogenous bone harvesting.  
   illustration of, 34f  
   local, 210  
   particulate, 34f, 46f, 48, 103f, 172f, 191f, 210, 343f  
   properties of, 32f, 32t  
   utilization of, 49f

vertical bone augmentation uses of, 106  
 xenografts and, 50

Autogenous bone harvesting  
 description of, 34, 44–48, 195–196  
 donor sites for  
   calvarium, 231–237, 232f–236f  
   iliac crest, 195–196, 225–231, 226f–230f  
   mandibular ramus, 220–223, 220f–223f, 238, 332f  
   mandibular symphysis, 214–219, 215f–216f  
   mandibular torus, 224  
   maxillary tuberosity, 210–211, 212f  
   palatal bone, 213–214, 215f–216f  
   parietal bone, 235–237, 236f  
   tibia, 224–225  
   zygomatic buttress, 211, 213  
 illustration of, 45f–46f, 78f, 191f, 316f  
 instrumentation for, 210

Azithromycin, 144t

## B

Barrier membranes, 18, 151–154, 169f, 341

Basal bone fracture, 309

Basic fibroblast growth factor, 83

Benign paroxysmal vertigo, 281

$\beta$ -tricalcium phosphate  
 with collagen, 60, 79  
 rhPDGF-BB and, 79  
 stem cells with, 87

Binder jetting, 85

Biologics  
 description of, 136  
 mesh grafting uses of, 196–199

Bio-Oss, 38f

Bio-PRF centrifuge, 56, 56f, 62

Bioprinting, 85

Bioresorbable scaffolds, 87

Bisphosphonates, 136

Block bone graft/grafting  
 allogeneic. *See* Allogeneic block grafts.  
 alloplastic, 246  
 autogenous. *See* Autogenous block bone grafts.  
 bone substitute blocks, 246–247  
 cortical. *See* Cortical block bone grafts.  
 corticocancellous blocks, 102, 105f  
 custom, 121, 246  
 handling of, 249, 249f  
 harvesting of. *See* Autogenous bone harvesting.  
 healing time for, 251  
 horizontal bone augmentation use of, 98–99  
 horizontal ridge deficiency treated with, 211f  
 implants with  
   long-term studies of, 252–254, 253f  
   outcomes of, 251–254  
   success/survival of, 251  
   textured-surface, 252  
 in interpositional bone grafting, 294–295, 295f–296f

recipient site preparation for, 248–249, 249f  
 rigid fixation of, 249  
 split bone block technique for, 237–244, 239f–244f, 251  
 volume gains, 251  
 wound dehiscence associated with, 339, 340f  
 xenogeneic, 246–247

Blood glucose, 134, 134t

BMACs. *See* Bone marrow aspirate concentrates.

BMPs. *See* Bone morphogenetic proteins.

BMSCs. *See* Bone marrow-derived mesenchymal stem cells.

Bone  
 alveolar. *See* Alveolar bone.  
 calcium for, 139  
 cancellous, 13, 14f  
 collagen matrix of, 12–13  
 compact, 13, 14f  
 ectopic, 42, 44f  
 extracellular matrix of, 12–13  
 growth of, 9, 10f  
 hierarchical structure of, 13  
 intramembranous, 9  
 lamellar structure of, 13  
 mineralized matrix of, 12–13  
 periosteum of, 11–12, 12f  
 properties of, 86  
 regeneration of, 17–19  
 repair abilities of, 17–18  
 structure of, 13–15  
 tissue compartments of, 11–13, 12f  
 width of, 1–3, 2f  
 woven, 13

Bone anabolic agents, 90–91

Bone augmentation  
 alveolar ridge. *See* Alveolar ridge augmentation.  
 angiogenesis for, 26  
 in anterior maxilla, 124, 332f  
 antibiotic prophylaxis before, 143, 144t  
 bone defect morphology and, 24  
 clinical evaluation for, 117–131  
 complications of, 158–159  
 dental evaluation before, 110, 129–131, 130f  
 digital guided, 121–122, 122f  
 digital radiography before, 117–120, 118f–120f  
 in esthetic zone, 110, 124–127  
 examples of, 24  
 flap design for, 313, 314f–317f  
 “graft less” approach, 109  
 guides for, 121  
 horizontal, 24f, 50  
 imaging before, 117–120, 118f–120f  
 before interpositional bone grafting, 297  
 maxillary implants treated with, 2, 27f–28f  
 Michigan Classification for, 98, 98t, 120  
 onlay, 250  
 PASS principles for, 26f, 26–27, 152  
 patient preparation for, 143–148

platelet-rich fibrin for, 58–61, 326f–328f  
 prosthetically guided, 117, 121  
 recipient site preparation for. *See* Recipient site preparation, for bone augmentation.  
 rhBMPs for, 71t–72t  
 rhPDGF-BB for, 73t, 80, 81f, 82  
 risk assessment before, 111  
 soft tissue evaluation before, 128, 129f  
 space creation/maintenance for, 27  
 surgical risks of, 111  
 vertical, 24–25, 50  
 virtual, 120f, 120–121

Bone cells  
 chondroblasts, 9–11, 10f  
 osteoblasts, 9–11, 10f, 13, 90  
 osteoclasts, 11, 33f, 33–34, 90  
 osteocytes, 10f, 11

Bone concavity, 24, 24f

Bone defects. *See also* Osseous defects.  
 bone grafting material affected by, 25–26, 50  
 classification of, 97–98  
 extrabony, 24–25  
 healing time affected by, 107  
 horizontal. *See* Horizontal bone defects.  
 intrabony, 24–25, 37, 50  
 morphology of, 24–26, 111  
 treatment options and outcomes affected by, 25  
 U-shaped, 170, 170f  
 vertical. *See* Vertical bone defects.

Bone expansion screws, 277, 277f

Bone formation  
 cells involved in. *See* Bone cells.  
 components for, 40, 41f  
 diabetes mellitus effects on, 134f  
 revascularization for, 153  
 scaffold for, 40

Bone graft(s)  
 allograft. *See* Allogeneic block grafts; Allografts.  
 alloplast. *See* Alloplast(s); Alloplastic block grafts.  
 autogenous. *See* Autogenous bone grafts.  
 cancellous, 209–210  
 cortical, 210  
 healing of, 362f–363f  
 in interpositional bone grafting, 294–295, 295f–296f  
 mandibular ramus, 108f, 220–223, 220f–223f, 238, 332f  
 membranous, 250  
 mesenchymal stem cells and, 90  
 platelet-rich fibrin and, 60  
 postoperative infection of, 340–341  
 remodeling of, 254  
 rhBMP-2 and, 75–76, 77f  
 socket, platelet-rich fibrin versus, 60  
 stability of, 27, 27f–28f  
 transplantation of, 18  
 vertical, 250  
 xenografts. *See* Xenogeneic block grafts; Xenografts.

- Bone grafting materials  
 biologic principles of, 40–44  
 bone defect effect on, 25–26, 50  
 classification of, 32f, 32t  
 guided bone regeneration use of, 154–155  
 horizontal bone augmentation use of, 106–107  
 indications for, 50–51  
 mesh grafting use of, 195–196, 196f  
 osteoconduction, 44  
 osteogenesis, 40  
 osteoinduction, 41–44, 43f–44f  
 overview of, 31  
 properties of, 44  
 regenerative properties of, 48f, 48–49  
 resorption of, 27  
 utilization of, 49f  
 vertical bone augmentation use of, 106–107
- Bone healing  
 alcohol consumption effects on, 138  
 periosteum's contribution to, 11  
 smoking effects on, 138, 141
- Bone height  
 for implant placement, 3–5, 5f  
 in posterior mandible, 5f  
 in posterior maxilla, 4f
- Bone loss, after tooth extraction, 7, 17
- Bone marrow, 13
- Bone marrow aspirate concentrates, 87, 90
- Bone marrow-derived mesenchymal stem cells, 87
- Bone morphogenetic proteins  
 in autogenous bone grafts, 155, 209  
 BMP-2, 42f, 48f, 76  
 in bone formation, 329  
 definition of, 70  
 inflammatory effects of, 75  
 mesenchymal stem cells and, 41  
 osteoblasts and, 33  
 osteoclasts and, 35, 37  
 periodontal regeneration uses of, 74  
 recombinant human. *See* rhBMP(s).  
 release of, from dentin grafts, 35  
 sinus floor augmentation uses of, 79
- Bone regeneration  
 angiogenesis in, 23f  
 biology of, 23  
 growth factors for, 70–83, 71t–74t  
 guided. *See* Guided bone regeneration.  
 protected, 169f, 170  
 signaling molecules for, 70–83
- Bone resorption  
 amount of, 4  
 after distraction osteogenesis, 307  
 osteoclasts in, 11  
 after tooth loss, 6
- Bone scrapers, 47f, 47–48, 77f, 152, 210, 317f
- Bone slurry, 46f
- Bone spreaders, 277f, 278
- Bone spreading, for ridge expansion, 266–274, 267f–274f
- Bone substitutes. *See also* Allograft(s); Alloplast(s); Xenografts  
 autogenous bone grafts and, 34, 106, 196  
 block grafts, 246–247  
 guided bone regeneration uses of, 50, 101, 152  
 mesh grafting use of, 196  
 platelet-rich fibrin and, 63–64
- Bone volume  
 description of, 1–3, 2f, 7  
 gains in  
 with block grafts, 251  
 with distraction osteogenesis, 306–307  
 with guided bone regeneration, 157–158  
 with interpositional grafting, 296, 306  
 with mesh grafting, 199  
 with ridge expansion, 280
- Bone-harvesting burs, 40, 41f, 47–48, 102f, 152
- Book flap, 271–272, 272f–273f, 278
- Buccal cortex fracture, 280, 281f
- Buccal flap, 162, 318–322, 318f–322f
- Bundle bone, 13
- Bupivacaine, 144
- Bupropion, 145t
- C**
- CAD. *See* Computer-aided design.
- Calcium, 139
- Calvarial bone harvesting, 231–237, 232f–236f
- CAM. *See* Computer-aided manufacturing.
- Canaliculi, 10f
- Cancellous allografts, 155
- Cancellous bone  
 description of, 13, 14f, 40  
 titanium mesh and, 195
- Cancellous bone grafts, 209–210
- Cannabis, 138
- Carbon monoxide, 137
- Cathepsin K, 11
- Cawood and Howell classification, 97
- CBCT  
 before bone augmentation, 117, 118f, 121, 130f  
 of maxilla, 334f
- Cefuroxime, 144t
- Cell therapy, 87–90, 88f–89f
- Chemotherapy, 136
- Chisels, 278, 278f
- Chlorhexidine rinse, 145, 341, 346
- Chondroblasts, 9–11, 10f
- Clarithromycin, 144t
- Clindamycin, 143
- Collagen membranes, 152–153, 155, 345
- Collagenated equine bone blocks, 294, 296f
- Collagenated porcine cortical bone lamina, 244
- Cologne ABC Risk Score, 110–111
- Cologne Classification of Alveolar Ridge Defects, 97
- Compact bone, 13, 14f
- Computer-aided design, 84, 84f, 120, 179
- Computer-aided manufacturing, 84, 84f, 122
- Computer-aided milling, 121
- Concentrated platelet-rich fibrin, 58
- Conical-connection implant, 2f
- Connective tissue grafts  
 epithelial, 126f, 128, 129f  
 keratinized mucosa augmentation uses of, 352–353, 354f–355f  
 subepithelial, 358, 359f
- Coronally advanced lingual flap, 322
- Coronally positioned palatal sliding flap, 326
- Cortical allografts, 155
- Cortical block bone grafts  
 calvarial, 104  
 combined horizontal and vertical bone defects reconstructed with, 104  
 description of, 34, 34f, 40, 210  
 exposure of, 343, 343f–344f  
 healing time for, 251  
 interpositional graft use of, 295f  
 mandibular, 104  
 resorption of, 250–251
- Cortical perforations, 26, 172f, 180f, 248, 316, 317f
- Corticocancellous block bone grafts  
 description of, 34, 34f, 36f, 102, 105f  
 exposure of, 345, 345f  
 from iliac crest, 249f, 250, 328f  
 immediate dentoalveolar restoration use of, 211  
 interpositional graft use of, 295f  
 mandibular reconstruction use of, 345, 345f  
 from tibia, 230
- COVID-related complications, 58
- Cranial mesoderm, 9
- Cranial neural crest, 9
- Craniomaxillofacial bone  
 growth of, 9  
 medullary cavity in, 12f, 13  
 periosteal, 12
- Crestal bone block, 238
- Crestal osteotomy, 271, 281f
- Cross-linked collagen membranes, 25, 81f, 99–100, 153, 154f, 157–158, 198, 346f
- Crown-abutment height space, 5, 5f
- Custom block bone grafts, 121, 246
- Customized mesh  
 advantages of, 194  
 in anterior maxilla, 183f–187f  
 buccal fixation screw securing of, 172f  
 mesh grafting uses of, 178f–195f, 179–195  
 particulate bone graft with, 191f  
 titanium mesh, 121, 180f–184f, 194
- Cylinder implants, 170f

## D

DBBM. *See* Deproteinized bovine bone mineral.

ddACM. *See* Dehydrated de-epithelialized amnion-chorion membrane.

Dehydrated de-epithelialized amnion-chorion membrane, 263, 274, 279

Delayed implant placement, 104–105

Demineralized freeze-dried bone allograft, 36, 37b, 42, 49f

Denosumab, 136

Densah burs, 278, 278f

Dense polytetrafluoroethylene membrane description of, 154, 163f, 346 titanium-reinforced, 101, 104, 176, 176f, 177f

Dental evaluation, 129–131, 130f

DentaMedica, 147–148

Dentin, autogenous, 34–35, 41

Deproteinized bovine bone mineral, 38f, 38–39, 82, 87, 90, 294

Dexamethasone, 144, 144t

DFDBA. *See* Demineralized freeze-dried bone allograft.

Diabetes mellitus, 133–135, 134f

DICOM files, 117, 121, 179

Digital guided bone augmentation, 121–122, 122f

Digital light processing, 85

Digital mock-up, 124–125, 125f

Digital radiography, 117–120, 118f–120f

Digital wax-up, 119f

Diplom, 13, 14f

Direct metal laser sintering, 85, 87, 122, 194

Distal releasing incisions, 315f, 320, 321f

Distraction osteogenesis advantages of, 305–306, 306b basal bone fracture secondary to, 309 bidirectional device for, 302f bone resorption after, 307 case examples of, 300f–303f complications of, 308–310, 309f–310f description of, 299 disadvantages of, 305–306, 306b extrasosseous devices for, 303, 303f–304f, 309f implant success/survival with, 308 indications for, 306 intraosseous devices for, 305 onlay bone grafting versus, 305 outcomes of, 306–308, 307f–308f palatal or lingual inclination of movement vector after, 310 in posterior mandible, 108 staging of, 307–308, 307f–308f surgical approach for, 299, 300f–303f vertical bone augmentation uses of, 100, 306–307 vertical bone defects treated with, 306–308 vertical osteotomies for, 299, 309–310 volume gains with, 306–307

Disuse atrophy, 16–17

dPTFE. *See* Dense polytetrafluoroethylene membrane.

DRESS syndrome, 143

Dual-energy x-ray absorptiometry, 136

Dynamic bone remodeling, 14

## E

Ecchymosis, 140, 140f

Ectopic bone, 42, 44f

Edema, postoperative, 144, 144t, 198–199

Edentulous maxilla, 2f

Electronic cigarettes, 138

Enamel epithelium, 20

Enamel matrix derivative, 80

Endochondral ossification, 9

Epithelial connective tissue graft, 126f

Esthetic zone bone augmentation in, 110 evaluation of, 124–127, 125f–127f vertical ridge defects in, 289

Expanded polytetrafluoroethylene membrane, 152, 154, 159, 346

External hex implant, bone loss around, 2f

Extrabony defects, 24–25

Extrasosseous devices, for distraction osteogenesis, 303, 303f–304f, 309f

Extrusion-based printing, 85

## F

Facial bone, 1, 6f

FDDBA. *See* Freeze-dried bone allograft.

Fibroblast growth factor-2, 70, 83

Fibrosis, 18

Fixed implant-supported partial denture, 304f

Fixed-angle centrifugation, 57

Flaps buccal, 318–322, 318f–322f closure of, 330–332, 332f design of, 313, 314f–317f full-thickness, 316 ischemia of, 339 lingual, 322–323, 323f–324f mucoperiosteal, 26, 124f, 131f, 186f, 189f, 202, 239f–240f, 315, 316f, 320f open-book, 313, 314f palatal description of, 324–326, 325f–326f, 330 rotated, 358–360, 361f periosteal, 320 release of, 318–326, 318f–326f safety, 320

4D printing, 87

Free epithelialized grafts, 352–353, 356, 356t, 357f–358f, 364

Free gingival graft, 128, 201, 358

Freeze-dried bone allograft, 36, 37b, 42, 49f

Full-thickness flap, 316

Functional ankylosis, 19–20

Fused deposition modeling, 85

## G

GDF-5, 83

Gene therapy, 79

Gerdy tubercle, 224

Glucocorticoids, 144

Glucometer, 134

Glycemic control, 135

Glycopyrrolate, 144t, 341

Glymatrix technology, 153

Growth factors. *See also specific growth factor.* bone regeneration uses of, 70–83, 71t–74t definition of, 70 indications for, 91 platelet-rich fibrin release of, 56, 56f, 327 wound healing benefits of, 246

Guide(s) bone augmentation, 121 surgical, for implant, 122–124, 123f

Guided bone regeneration advantages of, 152b alveolar ridge augmentation uses of, 166t barrier membranes for, 61, 151–155, 169f, 288f, 294, 296 bone grafting materials for allografts, 155 autogenous bone grafts, 44, 63f, 155 description of, 154–155 xenografts, 155 bone substitutes for, 50, 101, 152, 154 bone volume gains using, 157–158 clinical decision making for, 155–157, 156f–157f collagen membranes for, 100, 288, 294, 296, 345 complications of, 158–159, 341, 345 cortical perforations, 316, 317f description of, 25, 151–152 disadvantages of, 152b failed, 223f horizontal bone augmentation use of, 98–100, 107, 151, 155, 157–159 implant placement with illustration of, 154f success/survival of implant after, 159 mesh grafting and, 104, 169, 326 nonresorbable membranes for, 99 particulate autogenous bone for, 48 resorbable membranes with, 25, 104 rotated palatal flap in, 360 stages of, 166t suture removal after, 337f titanium mesh scaffolds for, 87 vertical bone augmentation use of description of, 100–101, 107–108, 151–152, 155, 157–158 mandibular, 159–162, 160f modified lingual flap advancement, 159, 161–162 zirconia shells for, 122

Guided surgery, 124, 124f

## H

Hard palate, 213  
 Hard tissue  
   reconstruction of, 353b, 354f  
   regeneration of, 91  
 HBA. *See* Horizontal bone augmentation.  
 Healing. *See* Bone healing; Wound healing.  
 Hemoglobin A1c, 134f, 134t, 134–135  
 Horizontal bone augmentation  
   bone grafting materials for, 106–107, 152  
   bone volume gains  
     with guided bone regeneration, 157–158  
     with mesh grafting, 199  
   complications of, 111  
   description of, 24f, 50  
   guided bone regeneration for  
     barrier membranes used in, 155, 166  
     bone volume gains with, 157–158  
     description of, 62, 98–100, 107, 151, 155  
   healing time for, 202  
   high, 99f, 99–100, 155  
   location-specific indications for, 107, 107t  
   low, 98–99, 99f  
   medium, 99, 99f, 155  
   Misch decision tree for, 98–100, 99f, 110  
   narrow-diameter implants versus, 108  
   onlay bone grafts for, 261  
   rhBMP-2 and titanium mesh for, 76  
   rhPDGF-BB for, 81f–82f  
   ridge expansion for, 261  
   sausage technique for, 63f, 155, 156f–157f  
   split bone block technique for, 238  
   techniques for, 98  
   vertical releasing incisions in, 313  
 Horizontal bone defects  
   description of, 97, 98t  
   in posterior mandible, 317f  
   vertical bone defects and, combination of, 102, 104, 160f–161f  
 Horizontal centrifugation  
   description of, 56, 57f  
   platelet-rich fibrin protocols via, 57–58  
 Horizontal mattress sutures, 331, 332f  
 Howship lacuna, 11  
 Hyaline cartilage, 11  
 Hydrocodone, 144, 144t  
 Hydrogen cyanide, 137  
 Hyperinflammatory state, 133

I

Ibuprofen, 144, 144t  
 IDR. *See* Immediate dentoalveolar restoration.  
 Iliac crest bone grafts  
   corticocancellous block, 249f, 250, 328f  
   harvesting of, 195–196, 225–231, 226f–230f, 249f  
   implants with, 252  
 Image-based scaffolds, 86–87  
 Immediate dentoalveolar restoration, 210

Immediate implant placement, 17  
 Implant(s)  
   cumulative survival rate for, 308  
   dehiscence defects, 24f  
   failure of, 146–147, 232f  
   guided surgery for, 124, 124f  
   indications for, 69  
   keratinized mucosa around, 351–352  
   marginal bone loss around, 254, 280, 297  
   narrow-diameter. *See* Narrow-diameter implants.  
   osseointegration of, 15  
   papilla height and, 125  
   platelet-rich fibrin applications, 64–65  
   proper positioning of, 117  
   provisional, 338  
   short. *See* Short implants.  
   stability of, 65  
   subperiosteal, 253f  
   surgical guides for, 122–124, 123f  
   survival/success of, 106  
     with block bone grafts, 251–252  
     with distraction osteogenesis, 308  
     with guided bone regeneration, 159  
     with interpositional grafting, 297  
     with mesh grafting, 199  
     with ridge expansion, 280  
   tapered, 279  
   textured-surface, 252  
   virtual planning of, 184f, 303f  
 Implant crown-abutment height space, 4  
 Implant placement  
   in block bone grafts and, 252, 253f  
   bone height for, 3–5, 4f  
   bone width for, 1–3, 2f  
   computer-guided template for, 192f  
   delayed, 104–105, 199, 225  
   factors that affect, 1  
   guided bone regeneration and, 154f  
   after interpositional bone grafting, 285  
   in posterior mandible, 174f  
   primary stability for, 19  
   ridge angulation effects on, 5–6  
   ridge expansion and, 98–99, 104, 107, 263, 279  
   simultaneous, 104–105, 252, 263, 274  
   staged, 105, 211, 252  
   submerged, 192f, 253f  
   tooth loss effects on, 6–7, 7f  
 Implant stability quotient, 64  
 Implant–bone interface, 15  
 Inferior alveolar nerve, 286, 297  
 Infrabony defects, 79  
 Injectable platelet-rich fibrin, 57  
 Inlay bone grafting, 285, 305. *See also* Interpositional bone grafting.  
 Insulin-like growth factors  
   description of, 83  
   IGF-1, 83  
   IGF-2, 70, 83  
 Interpositional bone grafting  
   advantages of, 285, 297b  
   in anterior mandible, 293–294, 297  
   in anterior maxilla, 108, 289–293, 290f–292f, 297

bone augmentation before, 297  
 bone graft materials, 294–295, 295f–296f  
 complications of, 297  
 cortical block bone graft for, 295f  
 corticocancellous block bone graft for, 295f  
 definition of, 285  
 description of, 25  
 disadvantages of, 285, 297b  
 implants with  
   marginal bone loss around, 297  
   placement of, 285  
   survival/success of, 297  
 indications for, 285  
 Le Fort I downfracture and, 108, 225  
 osteotomies for, 285, 287, 287f, 292  
 in posterior mandible, 286–289, 286f–289f, 296  
 vertical bone augmentation uses of, 100, 102  
 volume gains with, 296, 306  
 Intrabony defects, 24–25, 37, 50, 315f  
 Intramembranous bone, 9  
 Intraoral scan, 118, 119f  
 IntraSpin centrifuge, 62  
 i-PRF. *See* Injectable platelet-rich fibrin.  
 Island flap, 274, 274f, 278  
 ISQ. *See* Implant stability quotient.

## J

Jaw. *See also* Mandible.  
 atrophy of, 97–98, 339  
 medication-related osteonecrosis of, 90–91, 136–137, 137f  
 osteoradionecrosis of, 135–136, 136f

## K

Keratinized gingiva, 264, 351  
 Keratinized mucosa  
   description of, 201, 351  
   implant coverage by, 351–352  
   strategies for augmenting  
     connective tissue grafts, 352–353, 354f–355f  
     free epithelialized grafts, 352–353, 356, 356t, 357f–358f, 364  
     vestibuloplasty, 352–353

## L

Labial strip gingival graft, 354f  
 Landry index, 330  
 Lateral sinus floor elevation, 64f  
 Lateral window approach, 233f  
 Le Fort I osteotomy, 225, 285, 306  
 Lekholm and Zarb classification, 97  
 Leukocyte- and platelet-rich fibrin, 56–57  
 Lineage labeling, 12  
 Lingual flap, 322–323, 323f–324f  
 Long bone periosteal, 12  
 L-PRF. *See* Leukocyte- and platelet-rich fibrin.

## M

Macrophage colony-stimulating factor, 11, 33

Mandible. *See also* Jaw.  
atrophic, 4f  
bone defect of, 170f  
bone turnover in, 13  
corticocancellous block bone graft reconstruction of, 345, 345f  
embryologic development of, 15, 16f  
fracture of, 228f–229f  
growth of, 15, 16f  
masticatory loads on, 14  
maxilla versus, 14  
posterior. *See* Posterior mandible.  
vertical bone augmentation use of, 159–162, 160f

Mandibular implants, failed, 102f

Mandibular ramus bone harvesting, 220–223, 220f–223f, 238, 332f

Mandibular symphysis bone harvesting, 214–219, 215f–216f

Mandibular third molars, 15

Mandibular torus  
bone harvesting from, 224  
description of, 14

Masticatory loads, 14

Maxilla  
anterior. *See* Anterior maxilla.  
atrophic, 188f–189f, 233f, 344f  
bone turnover in, 13  
condensations in, 15  
embryologic development of, 15, 16f  
fracture of, 228f–229f  
fully edentulous, 181f  
growth of, 15, 16f  
mandible versus, 14  
masticatory loads on, 14  
palatal bone harvesting, 213–214, 215f–216f  
vertical bone defect in, 291f

Maxillary canines, congenitally absent, 43f

Maxillary central incisors, 123f, 241f

Maxillary implants  
failed, bone augmentation for, 2, 27f–28f  
fully guided placement of, 187f

Maxillary periosteum, 11

Maxillary sinus floor, 3. *See also* Sinus floor augmentation.

Maxillary tuberosity bone harvesting, 210–211, 212f

M-CSF. *See* Macrophage colony-stimulating factor.

Medication-related osteonecrosis of the jaw, 90–91, 136–137, 137f

Medullary cavity, in craniomaxillofacial bone, 12f, 13

Melt electrowriting, 85

Mental nerve, 318

Mesenchymal stem cells  
alveolar bone-derived, 90  
bone marrow-derived, 87  
description of, 40

## Mesh

CAD/CAM, 194f  
customized. *See* Customized mesh.  
exposure of, 171, 174f, 199–202, 200f  
surface of, 194, 195f  
titanium. *See* Titanium mesh.

Mesh grafting  
advantages of, 205b  
biologics for, 196–199  
bone grafting materials for, 195–196, 196f  
bone substitutes for, 196  
case study of, 333f  
customized mesh for, 178f–195f, 179–195  
disadvantages of, 205b  
guided bone regeneration and, 104, 169, 326  
horizontal bone augmentation use of, 98–100  
implant success/survival with, 199  
rhBMP-2 with, 199  
scaffolds for, 169f  
titanium mesh for. *See* Titanium mesh.

Michigan Classification for Bone Augmentation, 98, 98t, 120

Mini-implants, 338f

Misch and Judy classification, 97

Misch decision trees  
for horizontal bone augmentation, 98–100, 99f, 110  
for vertical bone augmentation, 100f, 100–102, 110

Modified lingual flap advancement, 159, 161–162

MRONJ. *See* Medication-related osteonecrosis of the jaw.

MSCs. *See* Mesenchymal stem cells.

Mucogingival junction, 162

Mucointegration, 20

Mucoperiosteal flaps, 26, 124f, 131f, 186f, 189f, 202, 239f–240f, 315, 316f, 320f, 335f, 362f

Mucosal thickness, 351

Mucosa-supported guides, 124

Mylohyoid muscle, 161

## N

Narrow-diameter implants  
in atrophic ridge, 1, 2f  
horizontal bone augmentation versus, 108  
occlusal view of, 76f  
titanium-zirconium, 3

Nasopharyngeal cancer, 135

Native collagen membranes, 153

Near-field electrospinning, 85

Nicotine, 137, 145t, 340

Nonresorbable membranes, 154

Nutrition, 139

## O

Obesity, 146

Occlusal examination, 131

Onlay bone augmentation, 250, 262

Onlay bone grafting, 285, 305

Open-book flap, 313, 314f

Oral anticoagulant therapy, 140

Oral epithelium, 20

Oral rinses, 145

ORN. *See* Osteoradionecrosis.

Oropharyngeal cancer, 135

Osseodensification burs, 277–278, 278f

Osseointegration, 15, 19–20, 135, 146

Osseous coagulum, 20

Osseous defects. *See also* Bone defects.  
morphology of, 24–26  
regeneration of, 23  
after tooth extraction, 18

Osseous healing, 133. *See also* Bone healing.

Osteoblasts, 9–11, 10f, 13, 33, 90

Osteoclasts, 11, 33f, 33–34, 90

Osteoconduction, 44, 154

Osteocytes, 10f, 11, 33–34, 44

Osteogenesis, 40, 154, 209

Osteoid, 13, 20

Osteoinduction, 41–44, 43f–44f, 49, 154

Osteopenia, 136

Osteoporosis, 90, 136–137

Osteoprogenitor cells, 19, 23, 40

Osteoprotegerin, 11

Osteoradionecrosis, 135–136, 136f

Osteotomes, 278

Osteotomies  
benign paroxysmal vertigo caused by, 281  
for bone harvesting, 220, 235  
complications of, 297  
crestal, 271, 281f  
for interpositional bone grafting, 285, 287, 287f, 292  
for ridge expansion, 266–274, 267f–274f, 276  
segmental, 289, 294, 296  
smile-shape, 288, 288f  
vertical, for distraction osteogenesis, 299, 309–310

Osterix, 9, 11

Oxidative stress, 146

## P

Pain management  
after bone augmentation, 144, 144t  
after iliac crest bone harvesting, 231  
after tibial bone harvesting, 225

Palatal bone harvesting, 213–214, 215f–216f

Palatal flap  
description of, 324–326, 325f–326f, 330  
remote, 162, 165  
rotated, 358–360, 361f

Palatal strip technique, 325f

Papilla shift technique, 320

- Parathyroid hormone, 90–91  
 Parietal bone harvesting, 235–237, 236f  
 Particulate bone grafts  
   combined horizontal and vertical bone defects reconstructed with, 102, 104  
   harvesting of, 210  
 PASS principles, 26f, 26–27, 152  
 Patient  
   initial assessment of, 117  
   risk assessment of, 110–111  
 PCL material, 86  
 PDGF. *See* Platelet-derived growth factor.  
 Penicillin, 143  
 Pericytes, 23, 44  
 Peri-implant bone regeneration  
   rhBMPs for, 72t  
   rhPDGF-BB for, 74t  
 Peri-implant mucosa, 351  
 Peri-implant mucositis, 352  
 Peri-implant tissue  
   health of, 159, 351–352  
   platelet-rich fibrin and, 64–65  
 Peri-implantitis, 139, 254, 352, 357f  
 Periodontal disease, 110, 129  
 Periodontal health, 129  
 Periodontal ligament, 14–15  
 Periodontitis, 110, 138, 188f, 294, 333f  
 Periosteal flap, 320, 322f  
 Periosteal grafts, 11  
 Periosteal releasing incisions, 319f, 320, 322f  
 Periosteal-elastic technique, 162, 319  
 Periosteoplasty, 320  
 Periosteum  
   description of, 11–12, 12f  
   osteoprogenitor cells in, 19  
 Piezoelectric saw blade, 276, 277f, 286, 287f  
 Platelet concentrates, 55  
 Platelet-derived growth factor, 56, 70, 79  
 Platelet-derived growth factor BB, 246  
 Platelet-poor plasma, 46f, 46–47, 62  
 Platelet-rich fibrin  
   allograft and, 61f  
   alveolar ridge augmentation uses of, 61–63  
   applications of, 47f  
   bone augmentation uses of, 58–61, 61f, 326f–328f  
   bone graft and, 62  
   bone substitutes and, 63–64  
   clots, 62  
   concentrated, 58  
   development of, 56  
   evolution of, 55–56  
   extraction site management uses of, 58–59  
   for extraction sockets, 60–61  
   growth factors released from, 56, 56f, 327  
   implant dentistry applications of, 64–65  
   injectable, 57  
   leukocyte-, 56–57  
   natural wound healing versus, 59  
   peri-implant tissue and, 64–65  
   sinus floor augmentation uses of, 63–64  
   socket bone graft versus, 60  
   sticky bone creation using, 170f  
 Platelet-rich plasma, 55  
 Pneumatization, 13  
 Podosomes, 33  
 Polyglycolic acid–trimethylene carbonate membrane, 153  
 Polytetrafluoroethylene membranes, 27, 152  
 Polytetrafluoroethylene suture, 331  
 Posterior mandible  
   atrophic, 108, 109f, 172f, 288f, 314f, 318  
   bone harvesting from, 223  
   bone height requirements in, 5f  
   customized titanium mesh in, 180f  
   horizontal bone defects in, 317f  
   implant placement in, 174f  
   interpositional bone grafting in, 286–289, 286f–289f, 296  
   lingual flap release in, 322  
   partially edentulous, 178f, 275f  
   ridge expansion in, 265f  
   short implants in, 288  
   titanium mesh in, 178f–180f  
   vertical bone deficiency in, 171f  
   vertical ridge augmentation in, 159, 175f, 296  
   zones of, 323f  
 Posterior maxilla, 203f, 212f  
   bone height requirements in, 4f  
   resorption of, 7f  
   vertical releasing incisions in, 315  
 Powder bed fusion, 85  
 Premaxilla, 15  
 Premaxillary suture, 9  
 Primary wound closure, 26, 152  
 Prosthetically guided bone augmentation, 117, 121  
 Protected bone regeneration, 169f, 170  
 Provisional prostheses, 332–339, 332f–339f  
 PRP. *See* Platelet-rich plasma.  
 Pseudoperiosteum, 173–174, 175f, 203, 347
- Q**  
 Quad zygomatic implants, 109
- R**  
 Radiation therapy, 135–136, 136f  
 RANKL, 11, 33, 137  
 Recipient site preparation  
   for block bone graft/grafting, 248–249, 249f  
   for bone augmentation  
     complications, 341–347  
     description of, 313  
     flap closure, 330–332, 332f  
     flap design, 313, 314f–317f  
     flap release, 318–326, 318f–326f  
     provisional prostheses, 332–339, 332f–339f  
     wound dehiscence, 339–341  
     wound healing, 326–330  
 Recombinant human bone morphogenetic protein-2. *See* rhBMP-2.  
 Regeneration, 17–19
- Regional acceleratory phenomenon, 202  
 Removable partial denture, 335  
 Resorbable membranes, for guided bone regeneration, 25, 104, 152, 182f  
 Resorbable suture, 331  
 Retromolar pad, 161  
 Revascularization, 153  
 rhBMP(s), 71t–72t  
 rhBMP-2  
   acellular collagen sponge and, 26, 42, 43f, 99, 101, 106, 196–198  
   allogeneic block grafts with, 246  
   allograft with, 50  
   alveolar ridge augmentation uses of, 79  
   alveolar ridge preservation uses of, 74  
   bone grafts and, 75–76, 77f  
   collagen sponge delivery of, 74, 104  
   description of, 40  
   disadvantages of, 197  
   edema caused by, 198–199  
   mesh grafting uses of, 196–199  
   socket preservation uses of, 75f  
   titanium mesh and, 76, 78f, 79  
   vertical bone augmentation uses of, 106  
   in wound healing, 329  
   xenogeneic block graft and, 79  
 rhBMP-7, 74  
 rhFGF-2, 83  
 rhGDE, 83  
 rhGDF-5, 83  
 rhIGF-1, 83  
 rhIGF-1 and, 83  
 rhPDGF-BB  
   alveolar ridge augmentation uses of, 82  
   alveolar ridge preservation uses of, 80, 81f–82f  
    $\beta$ -tricalcium phosphate and, 79  
   bone augmentation uses of, 80, 81f, 82  
   clinical applications of, 73t–74t, 79  
   deproteinized bovine block and, 246  
   mesh grafting uses of, 199  
   sinus floor augmentation uses of, 82–83  
   wound healing uses of, 329  
 Ribose cross-linked collagen membranes, 153, 346, 346f  
 Ridge expansion  
   advantages of, 261–262, 262t  
   biology of, 262–263, 263f  
   bone expansion screws for, 277, 277f  
   bone spreading for, 266–274, 267f–274f  
   book flap for, 271–272, 272f–273f, 278  
   buccal cortex fracture associated with, 280, 281f  
   complications of, 280–281, 281f  
   delayed, 274, 276  
   description of, 261  
   disadvantages of, 262, 262t  
   flap design for, 264–265, 265f–266f  
   flap management with, 262  
   flapless approach to, 265  
   full-thickness flap for, 265  
   healing time for, 262–263  
   horizontal bone augmentation use of, 98–99  
   immediate, 274, 276



- implants with  
 complications caused by, 280–281  
 marginal bone loss around, 280  
 placement of, 98–99, 104, 107, 263–264, 279  
 survival of, 280  
 instrumentation for, 276–279, 277f–278f  
 island flap for, 274, 274f, 278  
 maxillary, 270f  
 osseodensification burs for, 277–278, 278f  
 osseous morphology affected by, 262, 263f  
 osteotomies for, 266–274, 267f–274f, 276, 281f  
 in posterior mandible, 265f  
 simultaneous implant placement with, 262  
 single-stage approach, 274, 275t  
 split-thickness flap for, 265  
 staging of, 274–276, 275t  
 surgical techniques for, 264–274  
 tapered implants and, 279  
 three-stage approach, 275t, 276  
 two-stage approach, 274–276, 275t  
 vertical bone augmentation and, 262  
 volume gains with, 280
- Risk assessment, 110–111  
 Risk factors. *See* Systemic risk factors.  
 Rotated palatal flap, 358–360, 361f  
 Runx2, 9, 11, 19, 151
- S**
- SAC Classification, 110  
 SafeScraper, 47f  
 Safety flap, 320  
 Sausage technique, 63f, 155, 156f–157f, 353  
 Scaffolds  
 additive manufacturing production of, 84–86  
 bioresorbable, 87  
 description of, 40, 83–84  
 functionalization of, 85–86  
 image-based, 86–87  
 materials for, 85–86, 86f  
 mesh grafting use of, 169f  
 production of, 84f, 84–85  
 Scanning appliance, 118, 119f  
 Sclerostin-neutralizing monoclonal antibody, 90–91  
 Secretome, 40  
 Segmental osteotomies, 289, 294, 296  
 Selective laser sintering, 85–86  
 Short implants  
 in atrophic ridge, 5f  
 in posterior mandible, 288  
 survival of, 3  
 vertical bone augmentation versus, 108–109  
 Signaling molecules, 70–83  
 Simultaneous implant placement, 104–105  
 Single-stage ridge expansion, 274, 275t  
 Sintering, 85
- Sinus floor augmentation  
 bone marrow-derived stem cells in bone scaffold for, 88f  
 bone morphogenetic proteins for, 79  
 illustration of, 19f  
 platelet-rich fibrin for, 63–64  
 rhPDGF-BB for, 82–83
- Sinus floor elevation  
 bone marrow aspirate concentrate and deproteinized bone bovine mineral for, 87  
 rhBMPs for, 72t  
 rhPDGF-BB for, 74t
- Skeleton, 13–15  
 Smile-shape osteotomy, 288, 288f  
 Smoking  
 cessation of, 145t, 145–146  
 wound healing affected by, 137–138, 138f, 141, 340, 340f
- Snap-On Smile, 334, 336f  
 Social habits, 141
- Sockets  
 bone grafting in, 50  
 healing of, 17  
 illustration of, 24f  
 platelet-rich fibrin for, 60–61  
 rhBMP-2 for preservation of, 75f
- Soft tissue  
 defects of, 110  
 evaluation of, 128, 129f  
 healing of, 18, 60, 65, 329  
 keratinized mucosa, 201, 351–352  
 mucosal thickness, 351  
 peri-implant health affected by, 351–352  
 reconstruction of, 353b, 354f  
 strategies for thickening  
 subepithelial connective tissue graft, 358, 359f  
 thickness of, 6f
- Split bone block technique, 100, 237–244, 239f–244f, 251  
 Split-flap technique, 65  
 Standard tessellation language files, 118, 121
- Stem cells  
 definition of, 87  
 isolation of, 88f–89f  
 mesenchymal. *See* Mesenchymal stem cells.  
 therapeutic uses of, 87–90, 88f–89f
- Stereolithography, 85  
 Sterile technique, 145  
 Sticky bone, 58, 61f, 61–63, 102, 170f  
 STL files. *See* Standard tessellation language files.  
 Subepithelial connective tissue graft, 358, 359f  
 Submerged implants, 192f, 253f  
 Subperiosteal implant, 253f  
 Supracrestal tissue adhesion, 6, 20  
 Surgical guides, 122–124, 123f, 187f  
 Suspended internal-external suture, 331, 331f  
 Swing-out bucket centrifugation, 56  
 Systemic health, 110
- Systemic risk factors  
 alcohol, 138–139, 141  
 anticoagulants, 140, 140f  
 antiplatelet therapy, 140, 140f  
 chemotherapy, 136  
 diabetes mellitus, 133–135, 134f  
 nutrition, 139  
 osteoporosis, 136–137  
 osteoradionecrosis, 135–136, 136f  
 radiation therapy, 135–136, 136f  
 smoking. *See* Smoking.
- T**
- Tapered implants, 279  
 Teeth  
 ankylosed, 16  
 extraction of. *See* Tooth extraction.  
 loss of. *See* Tooth loss.
- Tenting screws, 101–102, 103f, 155, 157, 289f  
 Teriparatide, 91  
 TGF- $\beta$ . *See* Transforming growth factor  $\beta$ .  
 Third molar removal, 222  
 3D bioprinting, 85  
 3D constructs, 84  
 Three-stage ridge expansion, 275t, 276  
 Tibial bone harvest, 224–225  
 Tibial periosteum, 11  
 Tilted implants, 109  
 Tissue conditioners, 338  
 Tissue engineering, 70f  
 Tissue repair cells, 87  
 Titanium mesh  
 anterior maxilla reconstruction using, 336f  
 cancellous bone and, 195  
 computer-assisted manufacturing of, 122, 201  
 customized, 121, 180f–187f, 194  
 description of, 61  
 exposure of, 171, 174f, 199–202, 200f, 346, 347f  
 grafting technique for, 202–203, 204f  
 manufacturing of, 202  
 mesh grafting use of, 169–178, 170f–179f  
 pore size of, 173  
 in posterior mandible, 178f–179f  
 rhBMP-2 and, 76, 78f, 79  
 scaffolds, 87  
 soft tissue ingrowth of, 171  
 strip technique for, 203f–204f  
 surface modification of, 174, 176  
 thickness of, 173  
 vertical bone augmentation use of, 174f  
 wound dehiscence associated with, 339
- Titanium-reinforced dPTEF, 101, 104, 176, 176f, 177f, 199, 314f  
 Titanium-zirconium narrow-diameter implant, 3  
 Tobacco smoking. *See* Smoking.  
 Tooth extraction  
 bone loss after, 7, 17  
 immediate implant placement after, 17  
 osseous defect after, 18

- platelet-rich fibrin for site management  
after, 58–59  
site management after, 58–60  
socket healing after, 17
- Tooth loss  
bone resorption after, 6  
consequences of, 6–7, 7f  
implant placement affected by, 6–7, 7f
- Tooth-bone periodontal interface, 14
- Tooth-supported guides, 124, 242f
- Transforming growth factor  $\beta$ , 70
- Tunnel grafting, for horizontal bone  
augmentation, 98–99, 107
- 25-Hydroxy vitamin D, 146
- Two-stage ridge expansion, 274–276, 275t
- V**
- Vacuum-formed retainer, 334, 336f
- Varenicline, 145t
- Vascular endothelial growth factor, 56, 70, 199
- Vat polymerization, 85
- VBA. *See* Vertical bone augmentation.
- VEGF. *See* Vascular endothelial growth factor.
- Vertical bone augmentation  
in anterior mandible, 293–294  
in anterior maxilla, 162–165, 163f–165f  
autogenous bone grafts for, 106, 166  
block bone grafts for, 252  
bone grafting materials for, 50, 106–107  
bone volume gains  
with guided bone regeneration, 158  
with mesh grafting, 199  
complications of, 111  
description of, 24–25  
distraction osteogenesis for, 306–307  
in esthetic zone, 125  
flaps in  
design of, 320, 321t  
release of, 318–319  
guided bone regeneration for  
bone volume gains with, 158  
description of, 62, 107–108, 151–152, 155, 157–158  
mandible, 159–162, 160f–161f  
maxilla, 162–165, 163f–165f  
nonresorbable membranes used in, 155, 157, 166
- healing time for, 202  
high, 100f, 101–102, 157  
location-specific indications for, 107, 107–108  
low, 100f, 100–101  
mandibular, 159–162, 160f–161f  
maxillary, 162–165, 163f–165f  
medium, 100f, 101, 157  
Misch decision tree for, 100f, 100–102, 110  
rhBMP-2 and titanium mesh for, 76, 79  
rhPDGF-BB for, 81f–82f  
ridge expansion and, 262  
short implants versus, 108–109  
split bone block technique for, 238  
titanium mesh for, 174f, 197
- Vertical bone defects  
in anterior maxilla, 342f  
CBCT imaging of, 130f  
description of, 97, 98t  
distraction osteogenesis for, 306–308  
horizontal bone defects and,  
combination of, 102, 104, 160f–161f  
in maxilla, 291f  
in posterior mandible, 171f
- Vertical osteotomies, for distraction  
osteogenesis, 299, 309–310
- Vertical releasing incisions, 313, 315
- Vestibuloplasty, 128, 290f, 352–353
- Virtual bone augmentation, 120f, 120–121
- Vitamin C, 139, 330
- Vitamin D  
deficiency of, 146–147  
definition of, 146  
supplementation of, 139, 146–148, 148f  
testing of, 147–148
- W**
- Wnt signaling, 18, 90–91
- Wound  
dehiscence of, 62, 138f, 140, 297, 326, 339–341, 340f, 343  
primary closure of, 26, 152  
stability of, 27
- Wound healing  
conditions that affect, 141  
enhancing of, 326–327, 326f–330f  
growth factors for, 246  
natural, platelet-rich fibrin versus, 59
- platelet-derived growth factor effects  
on, 79  
process/phases of, 55, 140  
rhPDGF-BB for, 329  
signaling molecules in, 70–71  
smoking effects on, 137–138, 138f, 141, 340, 340f  
social habits that affect, 141  
soft tissue, 202  
vitamin C's role in, 139
- Woven bone, 13
- X**
- Xenogenic block grafts, 246–247
- Xenografts  
advantages and disadvantages of, 39  
autogenous bone grafts and, 50  
description of, 18–19, 37–39  
guided bone regeneration uses of, 155  
properties of, 32f, 32t  
rhBMP-2 and, 79  
sintering of, 37  
utilization of, 49f
- Z**
- Zirconia shells, 122
- Zygomatic buttress bone harvesting, 211, 213
- Zygomatic implants, 109